Role of paliperidone extended-release in treatment of schizoaffective disorder

References

• KasaninJThe acute schizoaffective psychoses. 1933Am J Psychiatry1994151Suppl 61441548192190
   PubMed Web of Science ®Google Scholar
• PeralaJSuvisaariJSaarniSILifetime prevalence of psychotic and bipolar I disorders in a general populationArch Gen Psychiatry200764192817199051
   PubMed Web of Science ®Google Scholar
• CanusoCMKosik-GonzalezCSheehanJFrequency of schizoaffective disorder diagnosis in patients with psychotic disorders using the mini-international neuropsychiatric interviewSchizophr Res20109830530620189355
   PubMed Web of Science ®Google Scholar
• KentSFogartyMYellowleesPHeavy utilization of inpatient and outpatient services in a public mental health servicePsychiatr Serv199546125412578590110
   PubMed Web of Science ®Google Scholar
• MattesJANayakDLithium versus fluphenazine for prophylaxis in mainly schizophrenic schizo-affectivesBiol Psychiatry1984194454496722235
   PubMed Web of Science ®Google Scholar
• BrockingtonIFKendellREKellettJMCurrySHWainwrightSTrials of lithium, chlorpromazine and amitriptyline in schizoaffective patientsBr J Psychiatry1978133162168354733
   PubMed Web of Science ®Google Scholar
• JanicakPGKeckPEJrDavisJMA double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorderJ Clin Psychopharmacol20012136036811476119
   PubMed Web of Science ®Google Scholar
• OkumaTYamashitaITakahashiRA double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disordersActa Psychiatr Scand1989802502592573234
   PubMed Web of Science ®Google Scholar
• ChengappaKNRDavidJKHaranathPA placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar typeBipolar Disord2007960961717845276
   PubMed Web of Science ®Google Scholar
• GreilWLudwig-MayerhoferWErazoNLithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: A randomised studyEur Arch Psychiatry Clin Neurosci199724742509088805
   PubMed Web of Science ®Google Scholar
• CheniauxELandeira-FernandezJLessaTLDoes schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disordersJ Affect Disord200810620921717719092
   PubMed Web of Science ®Google Scholar
• LindenmayerJPKaySRvanPHDistinction of schizoaffective from schizophrenic profile. Independent validationSchizophr Res198924234242487183
   PubMed Web of Science ®Google Scholar
• OlfsonMMarcusSCWanGJTreatment patterns for schizoaffective disorder and schizophrenia among Medicaid patientsPsychiatr Serv20096021021619176415
   PubMed Web of Science ®Google Scholar
• CraddockNJonesLJonesIRStrong genetic evidence for a selective influence of GABAA receptors on a component of the bipolar disorder phenotypeMol Psychiatry20101514615319078961
   PubMed Web of Science ®Google Scholar
• HamshereMLGreenEKJonesIRGenetic utility of broadly defined bipolar schizoaffective disorder as a diagnostic conceptBr J Psychiatry2009195232919567891
   PubMed Web of Science ®Google Scholar
• LenczTLipskyRHDeRossePBurdickKEKaneJMMalhotraAKMolecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypesBr J Psychiatry200919431331819336781
   PubMed Web of Science ®Google Scholar
• MalhiGSBerkMBourinMAtypical mood stabilizers: A “typical” role for atypical antipsychoticsActa Psychiatr Scand Suppl2005111Suppl 426293816104066
   PubMedGoogle Scholar
• DerrySMooreRAAtypical antipsychotics in bipolar disorder: Systematic review of randomised trialsBMC Psychiatry200774017705840
   PubMed Web of Science ®Google Scholar
• CruzNSanchez-MorenoJTorresFGoikoleaJMValentiMVietaEEfficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: A meta-analysisInt J Neuropsychopharmacol20101351419638254
   PubMed Web of Science ®Google Scholar
• KeckPEJrMcElroySLStrakowskiSMSchizoaffective disorder: Role of atypical antipsychoticsSchizophr Res199935SupplS5S1210190221
   PubMed Web of Science ®Google Scholar
• VietaEGoikoleaJMCorbellaBRisperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: Results from a 6-month, multicenter, open studyJ Clin Psychiatry20016281882511816872
   PubMed Web of Science ®Google Scholar
• LasserRBossieCAGharabawiGEerdekensMNasrallahHAEfficacy and safety of long-acting risperidone in stable patients with schizoaffective disorderJ Affect Disord20048326327515555724
   PubMed Web of Science ®Google Scholar
• TranPVTollefsonGDSangerTMLuYBergPHBeasleyCMJrOlanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapyBr J Psychiatry1999174152210211146
   PubMed Web of Science ®Google Scholar
• KeckPEJrReevesKRHarriganEPthe Ziprasidone Study GroupZiprasidone in the short-term treatment of patients with schizoaffective disorder: Results from two double-blind, placebo-controlled, multicenter studiesJ Clin Psychopharmacol200121273511199944
   PubMed Web of Science ®Google Scholar
• GlickIDMankoskiREudiconeJMMarcusRNTranQVAssunção-TalbottSThe efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: Results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trialsJ Affect Disord2009115182619230981
   PubMed Web of Science ®Google Scholar
• LevinsonDFUmapathyCMusthaqMTreatment of schizoaffective disorder and schizophrenia with mood symptomsAm J Psychiatry19991561138114810450252
   PubMed Web of Science ®Google Scholar
• McElroySLKeckPEJrStrakowskiSMAn overview of the treatment of schizoaffective disorderJ Clin Psychiatry199960Suppl 5162110192403
   PubMed Web of Science ®Google Scholar
• FlynnJGriegerTABenedekDMPharmacologic treatment of hospitalized patients with schizoaffective disorderPsychiatr Serv200253949611773657
   PubMed Web of Science ®Google Scholar
• CanusoCMLindenmayerJPKosik-GonzalezCA randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorderJ Clin Psychiatry20107158759820492853
   PubMed Web of Science ®Google Scholar
• CanusoCMSchoolerNCarothersJPaliperidone ER in schizoaffective disorder: A randomized controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizersJ Clin Psychopharmacol20103048749520814330
   PubMed Web of Science ®Google Scholar
• Invega^® (paliperidone) extended-release tablets [Prescribing Information]Titusville, NJJanssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc2010
   Google Scholar
• ConleyRRKellyDLDrug-drug interactions associated with second-generation antipsychotics: Considerations for clinicians and patientsPsychopharmacol Bull200740779717285099
   PubMed Web of Science ®Google Scholar
• VermeirMNaessensIRemmerieBAbsorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humansDrug Metab Dispos20083676977918227146
   PubMed Web of Science ®Google Scholar
• BerwaertsJCletonAHerbenVThe effects of paroxetine on the pharmacokinetics of paliperidone extended-release tabletsPharmacopsychiatry20094215816319585395
   PubMed Web of Science ®Google Scholar
• KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull1987132612763616518
   PubMed Web of Science ®Google Scholar
• YoungRCBiggsJTZieglerVEMeyerDAA rating scale for mania: Reliability, validity and sensitivityBr J Psychiatry1978133429435728692
   PubMed Web of Science ®Google Scholar
• HamiltonMDevelopment of a rating scale for primary depressive illnessBr J Soc Clin Psychol196762782966080235
   PubMed Web of Science ®Google Scholar
• AllenMHBartkoJJLindenmayerJPDevelopment and psychometric exploration of a clinical global impressions scale for schizoaffective disorder (CGI-SCA)Poster presented at 49th Annual New Clinical Drug Evaluation Unit Meeting2009 Jun 29–Jul 2Hollywood, FL
   Google Scholar
• MarderSRDavisJMChouinardGThe effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trialsJ Clin Psychiatry1997585385469448657
   PubMed Web of Science ®Google Scholar
• SimpsonGMAngusJWA rating scale for extrapyramidal side effectsActa Psychiatr Scand Suppl197021211194917967
   PubMedGoogle Scholar
• GuyWAbnormal Involuntary Movement ScaleECDEU Assessment Manual for PsychopharmacologyWashington, DCU.S. Public Health Service1976
   Google Scholar
• BarnesTRA rating scale for drug-induced akathisiaBr J Psychiatry19891546726762574607
   PubMed Web of Science ®Google Scholar
• SalvatorePBaldessariniRJTohenMMcLean-Harvard international first-episode project: Two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patientsJ Clin Psychiatry20097045846619200422
   PubMed Web of Science ®Google Scholar
• MeltzerHYBoboWVNuamahIFEfficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: Pooled data from three 6-week, placebo-controlled studiesJ Clin Psychiatry20086981782918466043
   PubMed Web of Science ®Google Scholar
• BerwaertsJCletonARossenuSA comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophreniaJ Psychopharmacol2010241011101819825908
   PubMed Web of Science ®Google Scholar